Navigation Links
Biovista Awarded Research Grant on Chronic Fatigue Syndrome From the CFIDS Association of America
Date:3/6/2012

CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ --

Biovista announced today that it has been awarded a prestigious research grant by the CFIDS Association of America to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS).

As part of its work, Biovista will share research outcomes with 5 top North American universities, such as Johns Hopkins, within the framework of the Association's "research institute without walls" initiative which stresses collaboration between 'tightly integrated projects led by experts in diverse disciplines' as CFIDS Association CEO Kimberly McCleary puts it.

Biovista will use its proprietary very-large-scale systematic drug repurposing platform called clinical Outcomes Search Space (COSS™) to identify drug candidates to treat CFS. "We are honored and excited to have received this prestigious grant award, which confirms our belief in the practicality of using drug repurposing to find treatments for diseases where the financials of drug development are an important parameter" said Dr. Aris Persidis, President of Biovista. "Biovista is seeking collaborations with leading Patient Advocacy Groups (PAGs) because of their extreme knowledge of the field and their access to data that can lead to effective personalized or optimized for specific sub-populations therapies. This is our second collaboration with a PAG following our work with the Thalassaemia International Federation and is well aligned with the company's goal for leading-edge work in the area of personalized medicine" he added.

"The partnership with Biovista through this grant represents an exciting opportunity to uncover potentially promising therapies for CFS using their 'agnostic' data-driven tools," Ms. McCleary stated. "The results of their search will also enhance our pursuit of biomarkers that can be used to target and monitor treatment. Their work alone will be powerful, but linking the Biovista project into our network of investigators and to the resources of our SolveCFS BioBank will greatly amplify the potential."

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for drugs and profiles their side effects using mechanism-of-action analytics. Biovista develops its own pipeline of drugs in CNS, oncology, auto-immune and rare diseases. Biovista is collaborating with biopharmaceutical companies on indication expansion and de-risking of their portfolios and with the FDA on adverse event prediction (http://www.biovista.com).

For further information please contact:

Aris Persidis
Biovista, Inc.
arisp@biovista.com
+1-434-242-6514



'/>"/>
SOURCE Biovista
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
2. Biovista Inc. Named Top Innovator in Life Sciences
3. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
6. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
7. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
8. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
9. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
10. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
11. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
(Date:2/8/2016)... Kan. , Feb. 8, 2016 /PRNewswire/ ... organization that formerly specialized in the development ... recently announced that it has divided its ... Capital. While Nueterra Capital will continue the ... services, NueHealth will operate a national system ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
Breaking Medicine Technology:
(Date:2/8/2016)... Park, KS (PRWEB) , ... February 08, 2016 , ... ... a leader in Mole removal products. , Moles are derived from a cluster of ... appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
Breaking Medicine News(10 mins):